Company intelligence / Profile preview

Venturis Therapeutics

Dallas, Texas, United Statesventuristherapeutics.com ↗
Ownership
Private
Development stage
Phase 2
01

Overview

Venturis Therapeutics is developing protein drug candidates that stimulate angiogenesis to treat diseases characterized by vascular insufficiency such as diabetic wounds, severe ischemic heart disease, and peripheral artery disease. Their lead candidate promotes new blood vessel growth in ischemic organs/tissues.

Therapeutic areas
EndocrinologyCardiovascular
Modalities
Protein drug candidates
Industry
Biotech
02

Drug pipeline

1 asset

fibroblast growth factor 1

2

Beyond the preview

Go deeper on Venturis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venturis Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call